276 related articles for article (PubMed ID: 25108880)
1. Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients.
Matsumoto K; Shigemi A; Takeshita A; Watanabe E; Yokoyama Y; Ikawa K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Sep; 44(3):242-7. PubMed ID: 25108880
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients.
Sasaki T; Takane H; Ogawa K; Isagawa S; Hirota T; Higuchi S; Horii T; Otsubo K; Ieiri I
Antimicrob Agents Chemother; 2011 May; 55(5):1867-73. PubMed ID: 21357301
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic simulation for the quantitative risk assessment of linezolid-associated thrombocytopenia.
Onita T; Ishihara N; Ikebuchi A; Yano T; Nishimura N; Tamaki H; Ikawa K; Morikawa N; Naora K
J Clin Pharm Ther; 2022 Dec; 47(12):2041-2048. PubMed ID: 35893441
[TBL] [Abstract][Full Text] [Related]
4. Proposal of initial and maintenance dosing regimens with linezolid for renal impairment patients.
Kawasuji H; Tsuji Y; Ogami C; Kimoto K; Ueno A; Miyajima Y; Kawago K; Sakamaki I; Yamamoto Y
BMC Pharmacol Toxicol; 2021 Mar; 22(1):13. PubMed ID: 33663616
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of linezolid and its major metabolites PNU-142300 and PNU-142586 in adult patients.
Sakurai N; Kawaguchi H; Abe J; Kuwabara G; Imoto W; Shibata W; Yamada K; Yasui H; Nakamura Y; Kakeya H
Pharmacotherapy; 2022 Sep; 42(9):707-715. PubMed ID: 35856168
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics/pharmacodynamics of linezolid in sepsis patients with and without continuous renal replacement therapy.
Ide T; Takesue Y; Ikawa K; Morikawa N; Ueda T; Takahashi Y; Nakajima K; Takeda K; Nishi S
Int J Antimicrob Agents; 2018 May; 51(5):745-751. PubMed ID: 29425834
[TBL] [Abstract][Full Text] [Related]
7. Reappraisal of Linezolid Dosing in Renal Impairment To Improve Safety.
Crass RL; Cojutti PG; Pai MP; Pea F
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31109977
[TBL] [Abstract][Full Text] [Related]
8. Evaluating linezolid dose regimens against methicillin-resistant Staphylococcus aureus based on renal function in populations with different body weight.
Zuo M; Sun Y; Zhao X; Xu G; Wang N; Chen J; Zhu L; Yang W; Zhao M
J Clin Pharm Ther; 2022 Dec; 47(12):2162-2169. PubMed ID: 36053892
[TBL] [Abstract][Full Text] [Related]
9. Dosage regimen and toxicity risk assessment of linezolid in sepsis patients.
Dou L; Meng D; Dong Y; Chen L; Han X; Fan D; Dong H
Int J Infect Dis; 2020 Jul; 96():105-111. PubMed ID: 32251797
[TBL] [Abstract][Full Text] [Related]
10. Dosage Strategy of Linezolid According to the Trough Concentration Target and Renal Function in Chinese Critically Ill Patients.
Wu F; Zhang XS; Dai Y; Zhou ZY; Zhang CH; Han L; Xu FM; Wang YX; Shi DW; Lin GY; Yu XB; Chen F
Front Pharmacol; 2022; 13():844567. PubMed ID: 35479324
[No Abstract] [Full Text] [Related]
11. [Clinical study of vancomycin for appropriate dosing in severe infective patients with augmented renal clearance].
Liu N; Zhang B; Liu Y; Tang J; Dong D; Gu Q
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2018 Jul; 30(7):646-651. PubMed ID: 30045791
[TBL] [Abstract][Full Text] [Related]
12. Dose optimisation of linezolid in critically ill patients based on a population pharmacokinetic model: A two-centre prospective interventional study.
Shi L; Zhang Y; Duan L; Huang L; Li J; Lu J; Zhuang Z; Yuan Y; Feng Z; Sun J; Liu X; Zhou Q; Xue H; Xu J; Tang L
Int J Antimicrob Agents; 2023 Aug; 62(2):106881. PubMed ID: 37301313
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis.
Buerger C; Plock N; Dehghanyar P; Joukhadar C; Kloft C
Antimicrob Agents Chemother; 2006 Jul; 50(7):2455-63. PubMed ID: 16801426
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, toxicity and clinical efficacy of linezolid in Japanese pediatric patients.
Ogami C; Tsuji Y; To H; Yamamoto Y
J Infect Chemother; 2019 Dec; 25(12):979-986. PubMed ID: 31208925
[TBL] [Abstract][Full Text] [Related]
15. Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients.
Shen K; Yang M; Fan Y; Liang X; Chen Y; Wu J; Yu J; Zhang H; Wang R; Zhang F; Hang J; Wen X; Li H; Shen L; Zhang Z; Wu S; Shen B; Huang W; Chang C; Shen Y; Ren H; Yuan Q; Song X; Luo X; Zhang H; Yang W; Yang J; Zhang J
Clin Infect Dis; 2018 Nov; 67(suppl_2):S256-S262. PubMed ID: 30423042
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Intravenous Linezolid in Premature Infants.
Thibault C; Kassir N; Goyer I; Théorêt Y; Litalien C; Moussa A; Ovetchkine P; Autmizguine J
Pediatr Infect Dis J; 2019 Jan; 38(1):82-88. PubMed ID: 29634620
[TBL] [Abstract][Full Text] [Related]
17. Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment.
Dong Y; Li Y; Zhang Y; Zhang T; Zhu L; Dong Y; Wang T
Basic Clin Pharmacol Toxicol; 2019 Oct; 125(4):353-359. PubMed ID: 31056857
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers.
Cho YS; Lim HS; Lee SH; Cho YL; Nam HS; Bae KS
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712654
[TBL] [Abstract][Full Text] [Related]
19. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions.
Cheng CN; Wu CC; Kuo CH; Wang CC; Wang JT; Lin YT; Jhang RS; Lin SW
J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):466-475. PubMed ID: 32600864
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients.
Tietjen AK; Kroemer N; Cattaneo D; Baldelli S; Wicha SG
Br J Clin Pharmacol; 2022 Feb; 88(4):1835-1844. PubMed ID: 34622478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
